VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has named Raju Willener as its new chief financial officer, effective immediately. The appointment comes as the company seeks to bolster its financial leadership amid ongoing development of its proprietary BiTAC platform and oncology pipeline.
Willener brings over three decades of international experience in global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a pivotal role in shaping the company's capital strategy and identifying strategic opportunities.
"We are thrilled to welcome Raju to the VERAXA team," said Antz. "His extensive financial expertise and proven track record in corporate development will be invaluable as we advance our pipeline and position VERAXA for long-term growth."
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025. During his tenure, he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
The appointment is significant for VERAXA as it navigates the complex landscape of oncology drug development. The company's focus on bispecific T cell engagers and antibody-drug conjugates (ADCs) requires substantial capital, and having a CFO with deep capital markets experience is critical. Willener's background in managing large investment portfolios and executing strategic transactions positions him well to support VERAXA's funding efforts and potential partnerships.
VERAXA's proprietary BiTAC technology, which stands for bispecific T cell engager-ADC conjugate, is designed to harness the power of the immune system to target and destroy cancer cells. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is rapidly advancing its pipeline into clinical development.
Industry analysts view the move as a positive signal for the company's maturity. "Bringing on a CFO of Willener's caliber indicates that VERAXA is preparing for significant corporate activities, whether that means raising capital, pursuing partnerships, or potentially exploring strategic options," said Dr. Emily Carter, a biotech analyst at MarketWatch.
VERAXA's newsroom provides updates on the company's progress, and investors are encouraged to review the full press release for more details. The company also reminds stakeholders of the forward-looking statements associated with such announcements, which are subject to risks and uncertainties as detailed in its SEC filings.
As VERAXA continues to develop its next-generation antibody-based therapeutics, the appointment of Willener underscores its commitment to building a premier engine for discovery and development, with a clear focus on bringing innovative cancer treatments to patients in need.
